The Scientist

» geron

Most Recent

image: Geron hESC Trial to Resume?

Geron hESC Trial to Resume?

By | May 27, 2014

Nearly three years after Geron shuttered its stem cell program, BioTime receives funding to relaunch a Phase 1 trial for spinal cord injury.

0 Comments

image: Geron’s Stem Cell Program Sold

Geron’s Stem Cell Program Sold

By | October 2, 2013

The company, which launched the first ever clinical trial for a human embryonic stem cell therapy before shuttering its stem cell arm, has finally struck a deal with BioTime.

0 Comments

image: Geron Sells Stem Cell Assets

Geron Sells Stem Cell Assets

By | January 8, 2013

BioTime finalizes a deal to buy Geron’s defunct human embryonic stem cell assets.

0 Comments

image: BioTime Seeks Geron Stem Cell Assets

BioTime Seeks Geron Stem Cell Assets

By | November 13, 2012

Two former Geron CEOs make a bid for the company’s defunct human embryonic stem cell business.

1 Comment

image: First hESC Trial Kaput

First hESC Trial Kaput

By | November 15, 2011

Geron is terminating a clinical trial testing a human embryonic stem cell treatment for spinal cord injury.

30 Comments

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
ProteinSimple
ProteinSimple
Advertisement
NeuroScientistNews
NeuroScientistNews